<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935766</url>
  </required_header>
  <id_info>
    <org_study_id>08-0722 LUCHAR AIM 4</org_study_id>
    <nct_id>NCT00935766</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries</brief_title>
  <official_title>Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional&#xD;
      contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk&#xD;
      factors in the prediction of pre-clinical CVD. Specific Aim 4.3 will test the impact of&#xD;
      omega-3 fatty acid supplementation on risk markers and pre-clinical markers of CVD in&#xD;
      Hispanic patients.&#xD;
&#xD;
      Specific Aim 4.3: Conduct a randomized, placebo-controlled trial of the effect of omega-3&#xD;
      fatty acid supplementation on vascular function as measured by brachial artery reactivity&#xD;
      (BAR) and on circulating inflammatory markers.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Daily omega-3 fatty acid supplementation will improve vascular function in subjects at&#xD;
           high risk for CVD.&#xD;
&#xD;
        2. Daily omega-3 fatty acid supplementation will reduce inflammatory protein panel scores&#xD;
           in subjects at high risk for CVD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Omega-3 fatty acids reduce triglycerides (TG) in a manner similar to fibric acids by lowering&#xD;
      hepatic TG release, reducing VLDL production, stimulating lipoprotein lipase and enhancing TG&#xD;
      clearance. Although statins are widely utilized among DH patients, our overall population,&#xD;
      even those with CHD, have fairly low levels of LDL-cholesterol (Krantz et al, 2004). This&#xD;
      likely reflects our population that is predominantly Latino with a high incidence of&#xD;
      metabolic syndrome. Among our patients, we often achieve LDL-c NCEP targets, yet secondary&#xD;
      goals for non-HDL, HDL, and TG are rarely achieved. This is an unmet opportunity given the&#xD;
      strong independent contribution of non-HDL (McQueen et al, 2008), HDL (D'Agostino et al,&#xD;
      2008) and TG (Nordestgaard et al, 2007, Tirosh et al, 2007) to CHD risk, which may be&#xD;
      particularly important in Latino populations.&#xD;
&#xD;
      The study drug (LOVAZA) improves the TC/HDL ratio which is the strongest predictor of CHD&#xD;
      events based on the ~30,000 patient Interheart study noted above. LOVAZA has no hepatic P450&#xD;
      effects and for that matter no meaningful clinical adverse effects, making it advantageous&#xD;
      for use in a population with multiple co-morbidities who are at risk for drug-drug&#xD;
      interactions and have difficulty with medication adherence. Given the high incidence of&#xD;
      insulin resistance among DH's predominately Latino CHD population, and strong lipid (Harris&#xD;
      et al, 1997; Davidson et al 2007) as well outcome data in CHD (GISSI investigators, 1999)&#xD;
      this agent has potential clinical utility in our population.&#xD;
&#xD;
      To date, improved outcomes in non-CHD populations have not been demonstrated prospectively&#xD;
      with LOVAZA. Although recent data suggest promising effects on inflammatory makers such as&#xD;
      LpPLA2, the impact of LOVAZA on pre-clinical markers of atherosclerosis such as BAR and CIMT&#xD;
      have not been well characterized particularly among Latinos. Moreover, changes in&#xD;
      inflammatory markers have been limited and more expansive evaluations are currently&#xD;
      available. Against this background we assessed whether LOVAZA might improve atherosclerotic&#xD;
      risk via improvement in flow mediated dilation of the brachial artery as well as through&#xD;
      reduction in a comprehensive inflammatory marker panel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was discontinued early due to lack of funding and slow enrollment&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>We conducted a prospective, randomized; double-blinded study of omega-3 fatty acids among 60 Latino and White hypertensive patients at risk for CVD. Patients received either 4-g omega-3 fatty acids or matched placebo daily. The principal outcome measure was change in brachial-ankle PWV.&#xD;
.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lipoprotein-associated Phospholipase A2 (LpPLA2)</measure>
    <time_frame>baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>baseline, 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Metabolic Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Heart Disease</condition>
  <condition>Vascular Diseases</condition>
  <condition>Diabetes</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 tabs of placebo dependent on randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.</description>
    <arm_group_label>Omega 3</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of HTN&#xD;
&#xD;
          -  Hispanic or Non-Hispanic White&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  One additional CVD risk factor&#xD;
&#xD;
               -  Age &gt; 55 for males or &gt;65 for females&#xD;
&#xD;
               -  DM&#xD;
&#xD;
               -  Dyslipidemia O TC &gt;220 or O LDL &gt;130 or O on statin therapy&#xD;
&#xD;
               -  Current smoker&#xD;
&#xD;
               -  Chronic kidney disease defined as GFR &lt;60 ml/min/1.72m2&#xD;
&#xD;
               -  BMI &gt; 30 kg/m2&#xD;
&#xD;
               -  Positive microalbuminuria -Able to sign consent form and willing to complete&#xD;
                  12-month follow- up period.&#xD;
&#xD;
        Exclusion criteria used for SA3/4 will also apply for Aim 4.3. These include factors&#xD;
        rendering assessment of endothelial function unreliable, such as:&#xD;
&#xD;
          -  Clinically manifest CVD (including angina, myocardial infarction, surgical or&#xD;
             percutaneous coronary revascularization, stroke, cerebrovascular revascularization,&#xD;
             peripheral vascular disease, heart failure, or valvular heart disease&#xD;
&#xD;
          -  Electrocardiographic evidence of prior myocardial infarction&#xD;
&#xD;
          -  Known valvular heart disease of at least moderate severity&#xD;
&#xD;
          -  Known left ventricular systolic dysfunction (LVEF &lt; 0.50)&#xD;
&#xD;
          -  End-stage renal disease&#xD;
&#xD;
          -  History of inflammatory disease or vasculitis (including rheumatoid arthritis,&#xD;
             systemic lupus erythematosis, Raynaud phenomenon, or other connective tissue&#xD;
             disease/vasculitides)&#xD;
&#xD;
          -  Corticosteroid therapy&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Projected life-expectancy &lt;12 months due to comorbid condition&#xD;
&#xD;
          -  Plans to move away from the Denver area within 12 months&#xD;
&#xD;
          -  Previous trauma or surgery of the brachial artery&#xD;
&#xD;
          -  Upper arm circumference exceeding 42 cm.&#xD;
&#xD;
        Additional exclusion criteria for participation in Aim 4.3 include:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Known sensitivity or allergy to fish&#xD;
&#xD;
          -  Known sensitivity or allergy to omega-3 fatty acid supplements&#xD;
&#xD;
          -  Taking omega-3 fatty acid supplements in the last 2 weeks- may participate after 2&#xD;
             week washout&#xD;
&#xD;
          -  Triglycerides &gt; 500 mg/dL.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) levels above 3x upper limit of normal&#xD;
&#xD;
          -  Not a good candidate for participation based on the opinion of the investigators.&#xD;
&#xD;
          -  Current therapy with a fibric acid derivative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlin S Long, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health Medical Center Chief of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <results_first_submitted>February 11, 2014</results_first_submitted>
  <results_first_submitted_qc>September 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2014</results_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Carlin Long</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Latinos Using Cardio Health Actions to Reduce Risk</keyword>
  <keyword>Omega three Fatty Acids</keyword>
  <keyword>Vascular Function and Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was discontinued early due to lack of funding and slow enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (Four 1-gram capsules daily)</description>
        </group>
        <group group_id="P2">
          <title>Omega 3</title>
          <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (Four 1-gram capsules daily)</description>
        </group>
        <group group_id="B2">
          <title>Omega 3</title>
          <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.8"/>
                    <measurement group_id="B2" value="62.3" spread="9.7"/>
                    <measurement group_id="B3" value="61.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipoprotein-associated Phospholipase A2 (LpPLA2)</title>
        <time_frame>baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (Four 1-gram capsules daily)</description>
          </group>
          <group group_id="O2">
            <title>Omega 3</title>
            <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipoprotein-associated Phospholipase A2 (LpPLA2)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="31.7"/>
                    <measurement group_id="O2" value="-18.1" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP</title>
        <time_frame>baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (Four 1-gram capsules daily)</description>
          </group>
          <group group_id="O2">
            <title>Omega 3</title>
            <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="4.4"/>
                    <measurement group_id="O2" value="-0.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.</title>
        <description>We conducted a prospective, randomized; double-blinded study of omega-3 fatty acids among 60 Latino and White hypertensive patients at risk for CVD. Patients received either 4-g omega-3 fatty acids or matched placebo daily. The principal outcome measure was change in brachial-ankle PWV.&#xD;
.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (Four 1-gram capsules daily)</description>
          </group>
          <group group_id="O2">
            <title>Omega 3</title>
            <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.</title>
          <description>We conducted a prospective, randomized; double-blinded study of omega-3 fatty acids among 60 Latino and White hypertensive patients at risk for CVD. Patients received either 4-g omega-3 fatty acids or matched placebo daily. The principal outcome measure was change in brachial-ankle PWV.&#xD;
.</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" spread="306"/>
                    <measurement group_id="O2" value="-97" spread="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (Four 1-gram capsules daily)</description>
        </group>
        <group group_id="E2">
          <title>Omega 3</title>
          <description>omega-3-acid ethyl esters (Four 1-gram capsules daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall furnish copies of any proposed publication or presentation to the Sponsor for review at least thirty (30) days in advance of the submission of such proposed publication or presentation to a journal, editor or other third party. The sponsor shall have thirty (30) days after receipt of said copies, to object to such proposed presentation or proposed publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was discontinued early due to lack of funding and slow enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carlin Long, MD</name_or_title>
      <organization>Denver Health Medical Center</organization>
      <phone>303-602-3899</phone>
      <email>carlin.long@dhha.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

